{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:04:01Z","timestamp":1789603441387,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"DOI":"10.7759\/cureus.116379","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:40:21Z","timestamp":1789602021000},"source":"Crossref","is-referenced-by-count":0,"title":["Gallium-68 (68Ga)-Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in the Initial Staging of High-Risk Prostatic Adenocarcinoma: Reclassification to Oligometastatic Disease and Change in Treatment Intent"],"prefix":"10.7759","author":[{"given":"Carlos Paul","family":"Villalba-Meneses","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana P","family":"Noboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica Marcela","family":"Villegas-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer EJ","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, et al.. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025, 87:302-13. 10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein JI","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016, 40:244-52. 10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging - Reporting and Data System: 2015, version 2","volume":"69","author":"Weinreb JC","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, et al.. PI-RADS Prostate Imaging - Reporting and Data System: 2015, version 2. Eur Urol. 2016, 69:16-40. 10.1016\/j.eururo.2015.08.052","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler WP","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, et al.. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023, 50:1466-86. 10.1007\/s00259-022-06089-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman MS","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al.. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020, 395:1208-16. 10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.006","article-title":"Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial","volume":"9","author":"Hofman MS","year":"2026","unstructured":"Hofman MS, Kasivisvanathan V, Link E, et al.. Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial. Eur Urol Oncol. 2026, 9:422-9. 10.1016\/j.euo.2024.11.006","journal-title":"Eur Urol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment","volume":"87","author":"Mazzone E","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, et al.. A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol. 2025, 87:654-71. 10.1016\/j.eururo.2025.03.003","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber M","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al.. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018, 59:469-78. 10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert R","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al.. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023, 83:405-12. 10.1016\/j.eururo.2023.02.002","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe SP","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018, 59:479-85. 10.2967\/jnumed.117.195255","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci F","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al.. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021, 48:1626-38. 10.1007\/s00259-021-05245-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263448","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett L","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, et al.. The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022, 63:1644-50. 10.2967\/jnumed.121.263448","journal-title":"J Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213404","article-title":"Fifty shades of PSMA-avid rib lesions: a comprehensive review","volume":"17","author":"Shamshirgaran A","year":"2025","unstructured":"Shamshirgaran A, Samadi MH, Saeed M, et al.. Fifty shades of PSMA-avid rib lesions: a comprehensive review. Cancers (Basel). 2025, 17:3404. 10.3390\/cancers17213404","journal-title":"Cancers (Basel)"},{"key":"ref15","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55.","journal-title":"Am J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia","volume":"148","author":"Barry MJ","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992, 148:1549-57. 10.1016\/s0022-5347(17)36966-5","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737-46. 10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018, 392:2353-66. 10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al.. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019, 381:121-31. 10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips R","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al.. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020, 6:650-9. 10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/529567-gallium-68-68ga-labelled-prostate-specific-membrane-antigen-positron-emission-tomographycomputed-tomography-in-the-initial-staging-of-high-risk-prostatic-adenocarcinoma-reclassification-to-oligometastatic-disease-and-change-in-treatment-intent","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:40:22Z","timestamp":1789602022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/529567-gallium-68-68ga-labelled-prostate-specific-membrane-antigen-positron-emission-tomographycomputed-tomography-in-the-initial-staging-of-high-risk-prostatic-adenocarcinoma-reclassification-to-oligometastatic-disease-and-change-in-treatment-intent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.116379","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}